8-K: Myomo Reports Record Revenue and Positive Cash Flow in Q4 2024, Issues Optimistic 2025 Guidance

Myomo, Inc. announces record revenue of $12.1 million and its first-ever positive quarterly cash flow from operations in Q4 2024, along with a revenue guidance of $50 million to $53 million for 2025.

Summary

• Myomo, Inc. reported its financial results for the fourth quarter and year ended December 31, 2024.
• Q4 2024 revenue reached a record $12.1 million, a 154% increase compared to Q4 2023.
• The company achieved positive cash flow from operations of $3.4 million in Q4 2024.
• A record 233 MyoPro authorizations and orders were received in Q4 2024.
• Myomo added a record 657 new candidates to the patient pipeline in Q4 2024.
• Gross margin for Q4 2024 was 71.4%, up from 65.3% in Q4 2023.
• The company's net loss for Q4 2024 was $0.3 million, or $0.01 per share, compared to a net loss of $2.5 million, or $0.07 per share, for Q4 2023.
• Adjusted EBITDA for Q4 2024 was $0.2 million, the first quarter of positive Adjusted EBITDA in the company's history.
• Full-year 2024 revenue was $32.6 million, a 69% increase compared to 2023.
• Myomo expects revenue for 2025 to be in the range of $50 million to $53 million, representing a 54% to 63% increase compared to 2024.
• The company aims to return to positive cash flow from operations on a quarterly basis by Q4 2025.

Sentiment

Score: 8

Explanation: The document presents a highly positive outlook with record revenue, positive cash flow, and optimistic future guidance. While there are risks, the overall tone is confident and suggests strong growth potential.

Positives

• Record revenue of $12.1 million in Q4 2024, representing a 154% increase year-over-year.
• First-ever positive quarterly cash flow from operations of $3.4 million in Q4 2024.
• Record 233 MyoPro authorizations and orders in Q4 2024, up 27% year-over-year.
• Record 657 new candidates added to the patient pipeline in Q4 2024, a 72% increase.
• Gross margin improved to 71.4% in Q4 2024, up from 65.3% in Q4 2023.
• Revenue from patients with Medicare Part B represented 57% of fourth quarter revenue.
• Cost per pipeline add decreased by 46% to $1,224 in Q4 2024.
• The company is targeting positive cash flow from operations on a quarterly basis by Q4 2025.

Negatives

• Operating expenses increased by 60% in Q4 2024, driven by higher payroll and headcount.
• The company reported a net loss of $0.3 million for Q4 2024, although it's a significant improvement from the $2.5 million loss in Q4 2023.
• Adjusted EBITDA for 2024 was $(5.1) million.

Risks

• The company's ability to obtain sufficient reimbursement from third-party payers for its products.
• The ability to scale the business to return to positive cash flow from operations on a quarterly basis by Q4 2025.
• Revenue concentration with Medicare and a particular insurance payer.
• Dependence on external sources for financing operations.
• Ability to maintain and grow its reputation and achieve market acceptance of its products.
• Ability to compete and succeed in a highly competitive and evolving industry.

Future Outlook

Myomo expects revenue for the first quarter of 2025 to be in the range of $9.0 million to $9.5 million and full-year 2025 revenue to be in the range of $50 million to $53 million. The company aims to return to positive cash flow from operations on a quarterly basis by the fourth quarter of 2025.

Management Comments

• 'Our success in the fourth quarter is the culmination of a transformational year for Myomo,' said Paul R. Gudonis, Myomo's Chairman and Chief Executive Officer.
• Mr. Gudonis also stated that the company rapidly scaled its operations to serve the Medicare Part B population and exited the year in the best position it's been in.
• Mr. Gudonis added that investments in the direct billing channel during the first half of 2025 are expected to result in accelerating revenue growth during the second half of the year.

Industry Context

Myomo's focus on wearable medical robotics for upper-limb paralysis positions it within the growing market for rehabilitation technology and assistive devices. The company's success in securing Medicare Part B reimbursement is a significant advantage, as it expands access to its MyoPro device for a larger patient population.

Comparison to Industry Standards

• While direct comparisons are difficult due to the unique nature of Myomo's product, companies like Ekso Bionics and ReWalk Robotics also operate in the exoskeleton and rehabilitation robotics space.
• Myomo's gross margin of 71.4% is relatively strong compared to other medical device companies, suggesting efficient cost management.
• The company's focus on Medicare reimbursement aligns with industry trends towards value-based care and expanding access to innovative medical technologies.

Stakeholder Impact

• Shareholders are likely to react positively to the record revenue, positive cash flow, and optimistic guidance.
• Employees may benefit from increased job security and potential for bonuses due to the company's improved financial performance.
• Patients will have increased access to the MyoPro device due to the company's focus on Medicare reimbursement.
• Suppliers may see increased demand for their products as Myomo scales its operations.

Next Steps

• Myomo will hold a conference call to discuss the results and answer questions.
• The company will focus on scaling its business and achieving positive cash flow from operations on a quarterly basis by Q4 2025.
• Myomo will continue to invest in its direct billing channel to drive revenue growth.

Key Dates